Synta Presents Data From Phase 1 Trial Of Ganetespib In HER2+ MBC

(RTTNews) - Synta Pharmaceuticals Corp. (SNTA) announced presentation of preliminary results from an investigator-sponsored phase 1 trial, to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer or MBC refractory to other HER2 inhibitors.

The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas.

The phase 1 trial was conducted by physicians at New York University Langone Medical Center and Memorial Sloan Kettering Cancer Center. It enrolled six heavily pretreated patients who received prior to entering the trial a median of 3.5 anti-HER2 treatments in the metastatic, including trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1).

Of the five patients evaluable for efficacy, partial tumor response was observed in one patient who remains on study, and four patients achieved stable disease ranging in duration from 11 to 29 weeks.

Median Progression Free Survival was 19.4 weeks and the observed Clinical Benefit Rate was 60 percent.

Consistent with previously reported results for ganetespib, diarrhea, and fatigue were the most common adverse events associated with the combination treatment and were mostly Grade 1 or 2 in severity.